PERSISTENCE OF Human papillomavirus AFTER TREATMENT IN CASES OF INVASIVE CERVICAL CANCER IN NORTH OF BRAZIL

ALEJANDRA MARIA MARADIAGA ORTEGA,YANA CARDOSO DE LIMA,BRENO LEONARDO DA SILVA, HELLEN THAÍS FUZII, PHD, FABIOLA ELLIZABETH VILLANOVA ; MARIA ROSANA RAMIREZ

CABA

Congreso; Reunion Conjunta de las Sociedades de Biociencias; 2017

SAIC,SAIB, SAI, SAA, SAB, SAB, SAFE, SAFIS, SAH, SAP

Abstract: In the Pará State, North of Brazil, cervical cancer is the most frequent gynecological malignancy in women; the incidence of this cancer was estimated in 820 new cases of cancer, according to the National Cancer Institute (INCA, 2016). The Human Papillomavirus (HPV) is a sexually transmitted infection and this virus is considered the causative agent of the cervical carcinoma; it has more than 200 different viral types, of these, some are oncogenic or high risk types. Objectives: To investigate the persistence of HPV-DNA in cervical samples before and after cancer treatment with radiotherapy and / or chemotherapy. Materials and methods: Twenty nine women attended at Ophir Loyola Hospital-Belém- PA with invasive cervical cancer were enrolled in the study. Two samples for each patient were collected (smear of the endo an ectocervix) before and after the oncological treatment (fifty-eight samples in total). The cervical samples were tested for the presence of HPV DNA using nested- polymerase chain reaction (PCR) with My9/11 and GP5/6 primers. Results: The presence of HPV was detected in 82% (24/29) of the samples of women before treatment and in 68% (20/29) in the samples of women that completed treatment. It was found that in 75% (18/24) of women the HPV virus persisted after treatment, 25% (6/24) cleared the infection (p=0,3). Conclusion: In our study the prevalence of HPV DNA detected by PCR for the entire group of women with invasive cervical cancer was 75% HPV-DNA persistence after radiotherapy and/or chemotherapy could be a predictor for disease recurrence or disease outcome.